Literature DB >> 22586630

Forty years of translational cancer research.

William N Hait1.   

Abstract

Forty years after the signing of the National Cancer Act, we have produced a stunning repository of scientific information that is being translated into better therapies for patients. Although challenges remain, many solutions have been adopted, leading to early signs of progress against some of humankind's most dreadful diseases. This Prospective attempts to highlight some of the approaches that have been successful and analyze some that have not, and peers into a future in which renewal of the investment in cancer research will produce further benefits for patients. ©2011 AACR.

Entities:  

Mesh:

Year:  2011        PMID: 22586630     DOI: 10.1158/2159-8290.CD-11-0196

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  6 in total

Review 1.  Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development.

Authors:  Abhijit Pal; Rajiv Shinde; Manuel Selvi Miralles; Paul Workman; Johann de Bono
Journal:  Nat Rev Clin Oncol       Date:  2021-03-24       Impact factor: 66.675

Review 2.  Colorectal Cancer: Basic and Translational Research.

Authors:  J J Zhou; S Zheng
Journal:  Gastrointest Tumors       Date:  2013-09-12

3.  First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

Authors:  Debashis Sarker; Joo Ern Ang; Richard Baird; Rebecca Kristeleit; Krunal Shah; Victor Moreno; Paul A Clarke; Florence I Raynaud; Gallia Levy; Joseph A Ware; Kathryn Mazina; Ray Lin; Jenny Wu; Jill Fredrickson; Jill M Spoerke; Mark R Lackner; Yibing Yan; Lori S Friedman; Stan B Kaye; Mika K Derynck; Paul Workman; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2014-11-04       Impact factor: 12.531

Review 4.  Imaging biomarker roadmap for cancer studies.

Authors:  James P B O'Connor; Eric O Aboagye; Judith E Adams; Hugo J W L Aerts; Sally F Barrington; Ambros J Beer; Ronald Boellaard; Sarah E Bohndiek; Michael Brady; Gina Brown; David L Buckley; Thomas L Chenevert; Laurence P Clarke; Sandra Collette; Gary J Cook; Nandita M deSouza; John C Dickson; Caroline Dive; Jeffrey L Evelhoch; Corinne Faivre-Finn; Ferdia A Gallagher; Fiona J Gilbert; Robert J Gillies; Vicky Goh; John R Griffiths; Ashley M Groves; Steve Halligan; Adrian L Harris; David J Hawkes; Otto S Hoekstra; Erich P Huang; Brian F Hutton; Edward F Jackson; Gordon C Jayson; Andrew Jones; Dow-Mu Koh; Denis Lacombe; Philippe Lambin; Nathalie Lassau; Martin O Leach; Ting-Yim Lee; Edward L Leen; Jason S Lewis; Yan Liu; Mark F Lythgoe; Prakash Manoharan; Ross J Maxwell; Kenneth A Miles; Bruno Morgan; Steve Morris; Tony Ng; Anwar R Padhani; Geoff J M Parker; Mike Partridge; Arvind P Pathak; Andrew C Peet; Shonit Punwani; Andrew R Reynolds; Simon P Robinson; Lalitha K Shankar; Ricky A Sharma; Dmitry Soloviev; Sigrid Stroobants; Daniel C Sullivan; Stuart A Taylor; Paul S Tofts; Gillian M Tozer; Marcel van Herk; Simon Walker-Samuel; James Wason; Kaye J Williams; Paul Workman; Thomas E Yankeelov; Kevin M Brindle; Lisa M McShane; Alan Jackson; John C Waterton
Journal:  Nat Rev Clin Oncol       Date:  2016-10-11       Impact factor: 66.675

5.  Why the Shift? Taking a Closer Look at the Growing Interest in Niche Markets and Personalized Medicine.

Authors:  Shannon Gibson; Hamid R Raziee; Trudo Lemmens
Journal:  World Med Health Policy       Date:  2015-03

6.  [Targeting the signaling pathways in cancer therapy].

Authors:  William C S Cho
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-09-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.